Indivior Appoints Tony Kingsley to the Board of Directors
Indivior PLC (NASDAQ/LSE: INDV) has appointed Tony Kingsley as an Independent Non-Executive Director to its Board, effective July 1, 2025. The appointment was supported by affiliates of Oaktree Capital Management. Kingsley, currently CEO of Stablix, Inc., brings extensive biopharmaceutical leadership experience, having previously served as CEO of Scholar Rock and TARIS Bio, and held senior roles at The Medicines Company and Biogen.
As an accomplished executive with expertise in commercial operations and clinical development, Kingsley will contribute to Indivior's mission of delivering treatments for opioid use disorder (OUD) and realizing the potential of SUBLOCADE®. His appointment strengthens Indivior's leadership in providing life-transforming OUD treatments.
Indivior PLC (NASDAQ/LSE: INDV) ha nominato Tony Kingsley come Direttore Non Esecutivo Indipendente nel suo Consiglio di Amministrazione, con effetto dal 1° luglio 2025. La nomina è stata supportata dalle affiliate di Oaktree Capital Management. Kingsley, attualmente CEO di Stablix, Inc., porta con sé una vasta esperienza nella leadership biofarmaceutica, avendo ricoperto in precedenza il ruolo di CEO presso Scholar Rock e TARIS Bio, oltre ad aver svolto ruoli dirigenziali presso The Medicines Company e Biogen.
In qualità di dirigente esperto con competenze nelle operazioni commerciali e nello sviluppo clinico, Kingsley contribuirà alla missione di Indivior di fornire trattamenti per il disturbo da uso di oppioidi (OUD) e di valorizzare il potenziale di SUBLOCADE®. La sua nomina rafforza la leadership di Indivior nell’offrire terapie che trasformano la vita dei pazienti con OUD.
Indivior PLC (NASDAQ/LSE: INDV) ha designado a Tony Kingsley como Director No Ejecutivo Independiente de su Junta Directiva, con efecto a partir del 1 de julio de 2025. El nombramiento contó con el apoyo de afiliados de Oaktree Capital Management. Kingsley, actualmente CEO de Stablix, Inc., aporta una amplia experiencia en liderazgo biofarmacéutico, habiendo sido anteriormente CEO de Scholar Rock y TARIS Bio, y desempeñado cargos senior en The Medicines Company y Biogen.
Como un ejecutivo destacado con experiencia en operaciones comerciales y desarrollo clínico, Kingsley contribuirá a la misión de Indivior de proporcionar tratamientos para el trastorno por uso de opioides (OUD) y de aprovechar el potencial de SUBLOCADE®. Su nombramiento fortalece el liderazgo de Indivior en ofrecer tratamientos que transforman vidas para el OUD.
Indivior PLC (NASDAQ/LSE: INDV)는 2025년 7월 1일부로 이사회에 독립 비상임 이사로 Tony Kingsley를 임명했습니다. 이 임명은 Oaktree Capital Management의 계열사들의 지지를 받았습니다. 현재 Stablix, Inc.의 CEO인 Kingsley는 이전에 Scholar Rock와 TARIS Bio의 CEO를 역임했으며, The Medicines Company와 Biogen에서 고위직을 맡는 등 풍부한 바이오제약 리더십 경험을 보유하고 있습니다.
상업 운영과 임상 개발에 전문성을 갖춘 뛰어난 경영진으로서 Kingsley는 오피오이드 사용 장애(OUD) 치료제 제공과 SUBLOCADE®의 잠재력 실현이라는 Indivior의 사명에 기여할 것입니다. 그의 임명은 OUD 치료제 제공에 있어 Indivior의 리더십을 강화합니다.
Indivior PLC (NASDAQ/LSE : INDV) a nommé Tony Kingsley en tant qu'administrateur non exécutif indépendant au sein de son conseil d'administration, à compter du 1er juillet 2025. Cette nomination a été soutenue par des affiliés d'Oaktree Capital Management. Kingsley, actuellement PDG de Stablix, Inc., apporte une vaste expérience en leadership biopharmaceutique, ayant précédemment été PDG de Scholar Rock et TARIS Bio, ainsi que des postes de direction chez The Medicines Company et Biogen.
En tant que cadre accompli, expert en opérations commerciales et développement clinique, Kingsley contribuera à la mission d'Indivior qui est de fournir des traitements pour le trouble lié à l'usage d'opioïdes (OUD) et à exploiter le potentiel de SUBLOCADE®. Sa nomination renforce le leadership d'Indivior dans la fourniture de traitements transformateurs pour l'OUD.
Indivior PLC (NASDAQ/LSE: INDV) hat Tony Kingsley zum unabhängigen nicht geschäftsführenden Direktor in seinen Vorstand berufen, mit Wirkung zum 1. Juli 2025. Die Ernennung wurde von Tochtergesellschaften von Oaktree Capital Management unterstützt. Kingsley, derzeit CEO von Stablix, Inc., bringt umfassende Führungserfahrung in der Biopharma-Branche mit, nachdem er zuvor als CEO von Scholar Rock und TARIS Bio tätig war und leitende Positionen bei The Medicines Company und Biogen innehatte.
Als erfahrener Geschäftsführer mit Expertise in den Bereichen kommerzielle Operationen und klinische Entwicklung wird Kingsley zur Mission von Indivior beitragen, Behandlungen für Opioidgebrauchsstörungen (OUD) bereitzustellen und das Potenzial von SUBLOCADE® zu realisieren. Seine Ernennung stärkt die Führungsposition von Indivior bei lebensverändernden OUD-Behandlungen.
- Appointment of highly experienced biopharmaceutical executive with proven track record
- Strategic addition to strengthen commercial and clinical development expertise
- Support from major stakeholder Oaktree Capital Management for the appointment
- None.
Tony Kingsley is an accomplished biopharmaceutical executive with a distinguished track record of building and leading organizations across multiple scientific disciplines, therapeutic areas, and stages of development and commercialization.
"I am pleased to announce Tony's appointment to the Indivior Board. He is an experienced biopharmaceutical leader recognized for his strategic vision, operational expertise, and ability to drive growth in complex, regulated environments," said David Wheadon, M.D., Chair of the Board of Indivior. "Tony's significant commercial and clinical development experience will be invaluable to Indivior as we work to realize the full potential of SUBLOCADE® and deliver value to all Indivior stakeholders."
"Indivior has a long and successful track record of addressing the opioid use disorder with its portfolio of medicines to make meaningful recovery possible," said Mr. Kingsley. "I look forward to working closely with the Board and management team to advance Indivior's mission and strengthen its position as a leader in delivering life-transforming treatments for opioid use disorder."
Mr. Kingsley currently serves as CEO and Director of Stablix, Inc., a biotechnology company pioneering deubiquitination therapeutics as novel modality. Prior to joining Stablix, Mr. Kingsley was President and CEO of Scholar Rock, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases driven by protein growth factors. Previously, he led TARIS Bio as President and CEO, guiding the company through its acquisition by Janssen Pharmaceuticals in 2019. Earlier in his career, Mr. Kingsley held a series of senior leadership roles, including President and Chief Operating Officer at The Medicines Company and Executive Vice President of Global Commercial Operations at Biogen, where he oversaw the launch and growth of multiple therapies in neurology and hemophilia. Prior to this, he held numerous senior general management roles in devices and diagnostics and was a partner at McKinsey & Company.
Mr. Kingsley graduated magna cum laude from Dartmouth College and received an M.B.A. from Harvard Business School.
About Indivior
Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat opioid use disorder (OUD). Our vision is that all patients around the world will have access to evidence-based treatment for OUD and we are dedicated to transforming OUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on its heritage in this category. Headquartered in
View original content to download multimedia:https://www.prnewswire.com/news-releases/indivior-appoints-tony-kingsley-to-the-board-of-directors-302490184.html
SOURCE Indivior PLC
FAQ
Who is Tony Kingsley and when will he join Indivior's (INDV) Board of Directors?
What is Tony Kingsley's background and experience before joining Indivior (INDV)?
How will Tony Kingsley's appointment benefit Indivior (INDV)?
What is Indivior's (INDV) main business focus?
